Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program.

ABSTRACT:

Background

Patients with type 2 diabetes (T2D) are predisposed to derangements in serum Magnesium (Mg), which may have implications for cardiometabolic events and outcomes. In clinical trials, participants with T2D randomized to sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown mild to moderate increases in serum Mg from baseline levels. This post hoc analysis assesses the relation between serum Mg with cardiovascular outcomes in 10,140 participants of the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program.

Methods

We evaluated the association of baseline serum Mg with the primary composite end point of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke, and tested whether this association is modified by baseline s

SUBMITTER: Wang KM 

PROVIDER: S-EPMC8279612 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature